Radiolabelled compounds in the development of cytotoxic agents

Current Pharmaceutical Design

Volumn 10, Issue 24, 2004, Pages 2923-2934

  Kairemo, Kalevi A J ^a,b,c   Tähtinen, Marja ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Cancer Targeting Technologies Oy   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cancer chemotherapies; Cytotoxic compounds; Pharmacodynamics; Pharmacokinetics; Positron emission tomography; Radionuclide imaging; Single photon emission tomography; Targeting

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; BILIRUBIN; BROMINE 76; CARBON 11; CARBON DIOXIDE; CYTOTOXIC AGENT; FLOXURIDINE PHOSPHATE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM 68; GROWTH FACTOR; INDIUM 111; IODINE 123; IODINE 124; IODINE 131; ISOTOPE; LIPOSOME; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; OXYGEN 15; PROTEIN; RADIOISOTOPE; RECEPTOR; TECHNETIUM 99M; TEMOZOLOMIDE; THYMIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 86; ZIRCONIUM 89;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TARGETING; GAMMA SCINTIGRAPHY; HUMAN; IMAGING; ISOTOPE LABELING; LIVER TOXICITY; MOLECULAR SIZE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; RADIOISOTOPE DECAY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; VOMITING; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4544230516     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383458     Document Type: Review

References (87)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Tatum JL, Hoffman JM. Congressional update: report from the Biomedical Imaging Program of the National Cancer Institute. Imaging drug development. Acad Radiol 2000; 7: 1007-8.
3. Eckelman WC, Watorhouse R, Frank R. Nuclear imaging and biomarkers in drug development using approved radiopharmaceuticals. J Clin Phamacol 2001; suppl 4S-6S.
4. Nestor M, Persson M, Cheng J, Tolmachev V, van Dongen G. Anniko M, et al. Biodistribution or the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods. Bioconjug Chem 2003; 14: 805-10.
5. Penate Medina O, Zhu Y, Kairemo K. Curr Pharm Design 2004; 10(??): ????-????. this issue.
6. Mintun MA, Welch MJ Sigel CJ Mathias JW. Breast Cancer: PET imaging of oestrogen receptors. Radiology 1988; 169: 45-8.
7. Huang SC Phelps ME. Principles of tracer kinetic modelling in positron tomography In: Phelps ME Mazziota JC, Schelbert HR Eds. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. Raven Press, New York 1986, 287-346.
8. Gunn RN, Yap JT, Wells P, Osman S, Price PM, Jones T. A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med 2000; 41: 706-11.
9. 124I]iododeoxyuridine. Cancer Res 2000; 60: 6245-35.
10. Saleem A, Yap Y, Osman S, Brady F, Suttle B, Lucas SV, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in vivo imaging of drug action. Lancet 2000; 355: 2125-31.
11. Cunningham VJ, Jones TJ. Spectral analysis of dynamic PET studies J Cereb Blood Flow Metab 1993; 13: 15-23.
12. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constant from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7
13. Bergström M, Grahnen A, Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003; 59: 357-66.
14. Yung WK, Albright RE, Olson J, Fredericks R, Fink K Prados MD, et al. A phase II study of temozolomide vs, procarbazine in patients with glioblastoma multiforme at First relapse Br J Cancer 2000; 83: 588-93.
15. Middleton MR, Grob JJ, Aaronson N. Fierlbeck G, Tilgen W, Seiter S, et al. Randomised phase III study of temozolomide vs. dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 2000; 18: 158-66.
16. Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. Br J Cancer 1998; 78: 652-61.
17. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. Potential antitumour agents: In vivo solid-tumour activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, J Med Chem 1987; 30: 664-69.
18. Finlay GJ, Marshall E, Mathews JH, Paull KD, Baguley BC. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 1993; 31: 401-406.
19. Baguley BC, Finlay GJ Selectivity of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol 1989; 25: 271-77.
20. Saleem A, Harte JAH, Mathews.JC, Osman S, Brady F Luthra SK, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide in patients with positron emission tomography. J Clin Oncol 2001; 19: 1421-29.
21. Twelves CJ Gardener C, Flavin A, Sludden J Dennis I, de Bono J et al. Phase 1 pharmacokinetic study of DACA (XR500): a novel inhibitor of isomerase 1 and 11. CRC Phase I/II Committee. Br J Cancer 1999; 80: 1786-91.
22. Osman S, Luthra SK, Brady F, Hume SP, Brown G, Harte RJ, et al. Studies on the metabolism of the novel antitumour agent [N-methyl-11C]N- [2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase 1 clinical tria1s. Cancer Res 1997: 57: 2172-80.
23. Meikle SR, Matthews JC, Brock CS, Wells P, Harte RJ, Cunningham VJ, et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 1998; 42: 183-93.
24. Propper DJ, de Bono J, Saleem A. Ellard S, Flanagan E Paul J, et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase 1 study of 120-hour intravenous infusion XR5000. J Clin Oncol 2003; 21: 203-10.
25. Pinedo HM, Peters GF, Fluorouracil: biochemistry and pharmacology.J Clin Oncol 1988; 6: 1653-64.
26. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987: 47: 2203-06.
27. Dimitrakopoulou A, Strauss LG, Clorius JH. Ostertag H, Schlag P, Heim M, et al. Studies with positron emission tomography after systemic administration of florine-18-uracil in patients with liver metastases from colorectal carcinoma.J Nucl Med 1993; 34: 1075-81.
28. 18F]uracil positron emission tomography (PET). Eur J Cancer 1993; 12:1682-86.
29. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997; 57: 3415-23.
30. 18F]fluorouracil in sensitive versus resistant lymphocytie leukemia in mice. Cancer Res 1977; 37: 2306-08.
31. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U. Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998; 83: 245-53.
32. Ahmed FY, Johnston SJ Cassidy J, Eniluracil treatment completetly inactivates dihydropyrimidine dehydrogenase in colorectal tumours. J Clin Oncol 1999; 17: 2439-45.
33. Bading JR, Yoo PB, Fissekis JD, Alauddin MM, D'Argenio DZ. Conti PS. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res 2003; 63: 3667-74.
34. Plaat B, Kole A, Mastik M, Hoekstra H, Molenaar W, Vaalburg W. Protein synthesis rate measured with L-[1-HC]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med 1999; 26: 328-32.
35. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and treatment of Cancer (EORTC) PET Study Group. Eur.J Cancer 1999; 35: 1773-82,
36. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-36.
37. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidinen as a new maker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-8.
38. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 1997; 17:1573-76.
39. Liu A, Carlson KE, Katzenellenbogen JA. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem 1992; 35: 2113-29.
40. Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 2002; 62: 5912-9.
41. Zhao Q, Tolmachev V, Carlsson J. Lundqvist H, Sundin J, Janson JC, et al. Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. Bioconjug Chem 1999; 10: 938-46
42. Bakir MA. Eccles S, Babich JW. Aftab N, Styles J, Dean CJ, et al. C-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992; 33: 2154-60.
43. Lu E, Wagner WR, Schellenberger U, Abraham JA, Klibanov AL, Woulfe S, et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 2003; 108: 97-103.
44. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-74.
45. 18F] fluoro-17-oestradiol in breast cancer: correlation with estrogen receptor status and response to sytemic theraphy. Clin. Cancer Res 1996; 2: 933-9.
46. 18F]fluoro- 17 beta- estradiol uptake in metastatic breast carcinoma J Nucl Med 1991; 32: 1526-31.
47. Folkman J. Angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
48. Jekunen A, Kairemo K. Inhibition of angiogenesis at endothelial cell level. Microse Res Tech 2003; 60: 85-97,
49. Poon RT, Fan ST, Wong J. Clinical applications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
50. Miller KD, Sweeney CJ, Sledge GW. Redifining the target: chemotherapeutics as antiangiogenesis. J Clin Oncol 2001; 19: 1195-1206.
51. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A, Pirich C, et al. Imaging gastrointestinal tumors using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003; 14: 1274-7.
52. Weber WA, Haubner R, Vabuliene E, Kühnast B, Webster HJ, Schwaiger M. Tumour angiogenesis targeting using imaging agents. Q J Nucl Med 2001; 45: 179-82.
53. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphati-dylserine expression during programmed cell death Proc Natl Acad Sci 1998; 95: 6349-54.
54. Blankenberg FG, Trauss HW. Will imaging of apoptosis play a role in clinical care? A tale of mice and men Apoptosis 2001; 61: 117-23.
55. Collingridge DR, Glaser M, Osman S, Barthel H, Hutchinson OC, Luthra SK, et al. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003; 89: 1327-33.
56. Bellamy WT, Dalton WS, Dorr RT. The clinical relevance of multi-drug resistance. Cancer Invest 1990; 8: 547-62.
57. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
58. Chen CC, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using TE-99m sestamibi. Clin. Cancer Res 1997; 3: 545-52.
59. Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, et al. In vivo detection of multi-drug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24: 150-9.
60. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999; 59: 2411-16.
61. 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med 2000; 41: 493-501.
62. Brady F. Luthra S, Brown G, Osman S, Aboagye E, Saleem A. et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des 2001; 7: 1863-92.
63. Casciari JJ, Graham MM, Rasey JS. A modelling approach for quantifying hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys 1995; 22: 1127-39.
64. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-8.
65. 18F]fluoromisonidazole: a pretheraphy study of 37 patients, Int J Radiat Oncol Biol Phys 1996, 36, 417.
66. Zarzonico P, O'Donoghue J. Chapman JD, Schneider R, Cai S, Larson S, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of hypoxia in mice with serial microPET scanning. Eur J. Nucl Med Mol Imaging 2003 Oct 2,[Epub ahead of print].
67. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging 2003;30: 844-50.
68. Lu E, Wagner WR, Schellenberger U, Abraham JA, Klibanov AL, Woulfe SR, et al. Targeted in vivo labelling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 2003; 108: 97-103.
69. Weissleder R. Molecular imaging: exploring the next frontier. Radiology 1999; 212: 609-14.
70. Wunderbaldinger P, Bogdanov A, Weissleder R. New approaches for imaging in gene therapy. Eur J Radiol 2000; 34: 156-65.
71. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R. Imagimg herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 1998; 58: 4333-41.
72. Gambhir SS, Barrio JR, Phelp ME, Iyer M, Namavari M, Satyamurthy N, et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci 1999; 96: 2333-38.
73. Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) For PET imaging of HSV1-tk gene expression. J Nucl Med 2002; 43: 1072-83.
74. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 2003; 21: 405-13.
75. Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, et aL. Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med 2001; 7: 859-63.
76. Shih LB, Goldenberg DM, Xuan H, Lu H, Sharkey RM, Hall TC. Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. Cancer Res 1991; 51: 4192-8.
77. Yao Z, Zhang M, Sakahara H, Saga T, Arano Y, Konishi J. Avidin targeting of intraperitoneal xenografts. J Natl Cancer Inst 1998; 90: 25-9.
78. 131I-methylene blue: preclinical and clinical experience. Hybridoma 1999; 18: 77-82.
79. Howell RW, Kassis AI, Adelstein SJ, Rao DV, Wright HA, Hamm RN, et al. Radiotoxicity of platinum-195m-labeled trans-platinum (II) in mammalian cells. Radiat Res 1994; 140: 55-62.
80. Areberg J, Wennerberd J, Johnsson A, Norrgren K, Mattsson S. Anti effect of radioactive cisplatin (191 Pt) on nude mice. Int J Radiat Oncol Biol Phys 2001; 49: 827-32.
81. Hou DY, Maruyama Y, Drago JR. Chromosome aberrations of human small cell lung cancer induced by a new 111 In-bleomycin complex. J Surg Oncol 1992; 51: 236-42.
82. Kairemo K, Jekunen A, Ramsay H, Jaaskela-Saari H. Use of bleomycin in radiochemotherapy. J Nucl Med 1995; 36: 1531-2.
83. Jääskelä-Saari HA, Kairemo KJA, Ramsay HA, Grenman R. Labelling of bleomycin with Auger-emitter increases cytotoxicity in squamous-cell cancer cell lines. Int J Radiat Biol 1998; 73: 565-70.
84. Kairemo KJA, Ramsay HA, Tagesson M, Jekunen AP, Paavonen TK, Jääskelä-Saari HA, et al. Indium- 111 bleomycin complex for radiochemotherapy of head and neck cancer-dosimetric and biokinetic aspects. Eur J Nucl Med 1996; 23: 631-8.
85. Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Design 2003; 9(11): 931-44.
86. Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Pharmacokinetics or radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Design 2003; 9(11): 917-29.
87. Zunino F. Dallavalleb S. Laccabuea D, Berettaa G, Merlinib L, Pretesi G, Current status and perspectives in the development of camptothecins. Curr Pharm Design 2002; 8(27): 2505-20.